Efimosfermin alfa
Based on 1 Customer Validation
Efimosfermin alfa is a genetically engineered FGF21 variant. Efimosfermin alfa exerts its function by activating the FGFR1c/β-Klotho complex. Efimosfermin alfa is applicable to researches on metabolic dysfunction-associated steatohepatitis, obesity and mild hypertriglyceridemia.
For research use only. We do not sell to patients.
- Purity : 99%
- CAS No.: 2765640-39-7
- Molecular Weight:89.11 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Efimosfermin alfa works by activating the FGFR1c/β-Klotho complex.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Verified Bioactivity
-
Measured in a cell proliferation assay using NIH-3T3 mouse embryonic fibroblast cells. The ED50 for this effect is 0.3816 μg/mL in the presence of 1.25μg/mL Klotho beta, corresponding to a specific activity is 2.62×10^3 units/mg.
Product Details
-
CAS No. 2765640-39-7
-
Synonyms BOS-580; LLF580
-
Molecular Weight 89.11 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Format
-
FPIA_FC-[PROTEIN]2
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
References
[1]. Loomba R, et al. Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2025;10(8):734-745. [Content Brief]
[2]. Cui X, et al. Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment. Front Pharmacol. 2025 Apr 22;16:1510322. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)